Direxion Daily S&P 500 Bear 3X (ARCA: SPXS)

Ultime notizie per Direxion Daily S&P 500 Bear 3X (ARCA:SPXS)

Direxion Daily S&P 500 Bear 3X

Direxion

The fund, under normal circumstances, invests in swap agreements, futures contracts, short positions or other financial instruments that, in combination, provide inverse (opposite) or short leveraged exposure to the index equal to at least 80% of the funds net assets (plus borrowing for investment purposes). The index is a float-adjusted, market capitalization-weighted index. The fund is non-diversified.

Dreyfus Govt Cash Man Ins

Gs Financial Square Treasury Instruments Fund

Goldman Sachs Fin Gov 465 Institut

Dreyfus Trsy Prime Cash Mgmt - In 0 -

Direxion Daily S&P 500 Bear 3X Shares

Spirax Group PLC

SPIRAX GROUP PLC UNSP/ADR by SPIRAX GROUP PLC

PROG Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRG#NYSE">PRG</a>) reported quarterly earnings of $1.02 per share which beat the analyst consensus estimate of $0.81 by 26.71 percent. This is a 10.87 percent increase over earnings of $0.92 per share from the same period last year. The company reported quarterly sales of $604.663 million which beat the analyst consensus estimate of $585.665 million by 3.24 percent. This is a 2.11 percent increase over sales of $592.161 million the same period last year.

Earnings

Earnings Beats

News

PROG Holdings Q2 Adj. EPS $1.02 Beats $0.81 Estimate, Sales $604.663M Beat $585.665M Estimate

M/I Homes (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MHO#NYSE">MHO</a>) reported quarterly earnings of $4.42 per share which beat the analyst consensus estimate of $4.39 by 0.68 percent. This is a 13.67 percent decrease over earnings of $5.12 per share from the same period last year. The company reported quarterly sales of $1.16 billion which beat the analyst consensus estimate of $1.12 billion by 4.01 percent. This is a 4.50 percent increase over sales of $1.11 billion the same period last year.

M/I Homes Q2 EPS $4.42 Beats $4.39 Estimate, Sales $1.16B Beat $1.12B Estimate

Abivax SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABVX#NASDAQ">ABVX</a>) stock is skyrocketing on Wednesday after the clinical-stage biotechnology company announced overwhelmingly positive topline results from its Phase 3 ABTECT-1 (Study 105) and ABTECT-2 (Study 106) 8-week induction trials for oral obefazimod (ABX464) in adult patients with moderately to severely active <a href="https://www.benzinga.com/general/health-care">ulcerative colitis</a>. 
The Paris-based company achieved a significant breakthrough with its experimental treatment, which demonstrated impressive efficacy and offers new promise to patients afflicted with this <a href="https://www.benzinga.com/pressreleases/25/07/g46558444/abivax-announces-positive-phase-3-results-from-both-abtect-8-week-induction-trials-investigating-o">chronic bowel ailment</a>.
The ABTECT-1 and ABTECT-2 induction trials are assessing once-daily oral administration of obefazimod at 25 mg or 50 mg doses in adult patients with moderately to severely active ulcerative colitis. ABTECT-1 and ABTECT-2 were conducted simultaneously and have enrolled 1,275 patients.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/43053632/fda-approves-expanded-use-of-eli-lillys-ulcerative-colitis-drug-for-crohns-disease" rel="noreferrer noopener">FDA Approves Expanded Use Of Eli Lilly&#8217;s Ulcerative Colitis Drug For Crohn&#8217;s Disease</a>
Results from the ABTECT-1 and ABTECT-2 trials demonstrated that obefazimod met its FDA primary endpoint of clinical remission at Week 8 in the 50 mg once-daily dose regimens for both trials.
Individually, ABTECT-1 showed a placebo-adjusted clinical remission rate of 19.3% (p&lt;0.0001) and ABTECT-2 demonstrated 13.4% (p=0.0001), each at the 50 mg once-daily dose, with all key secondary efficacy endpoints being met.
The 25 mg once-daily dose of obefazimod achieved the FDA primary endpoint of clinical remission at Week 8 in ABTECT-1, demonstrating a placebo-adjusted remission rate of 21.4%.
While the 25 mg dose did not achieve statistical significance for this endpoint in ABTECT-2, it achieved a pooled placebo-adjusted clinical response rate of 28.6%, indicating a strong signal for these patients to achieve clinical remission with extended treatment in the maintenance trial.
The safety profile of obefazimod remained consistent with prior clinical experience. No new safety signals were observed in either trial, and the treatment was generally well tolerated across both dose groups.
Ongoing ABTECT Phase 3 Maintenance Trial:
<ul class="wp-block-list">
<li>678 of 1,275 participants entered Part 1, the responder cohort.</li>
<li>Topline maintenance results are expected in Q2 2026, which are intended to support regulatory filings globally.</li>
<li>Contingent on positive 44-week maintenance results, Abivax intends to submit a New Drug Application to the U.S. Food and Drug Administration and a Marketing Authorization Application to the European Medicines Agency in the second half of 2026.</li>
</ul>
The company has postponed its first-half 2025 financial results announcement from August 11 to September 8, 2025. As of June 30, 2025, it had about $71.4 million (or 61.0 million euros) in cash and cash equivalents.
In March, Palatin Technologies Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PTN#NYSE">PTN</a>) shared topline results from its Phase 2 study of PL8177, a selective melanocortin-1 receptor (MC1R) agonist, in patients with <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44536083/palatin-technologies-touts-positive-results-from-mid-stage-study-for-experimental-drug-for-ulcerative-colitis-halts-patients-enrollment-citing-strategic-focus" rel="noreferrer noopener">active ulcerative colitis</a>.
The company said clinical remission was achieved in 33% (3 of 9) of PL8177-treated patients versus 0% (0 of 3) on placebo.
Clinical response (statistically significant) was demonstrated in 78% (7 of 9) of PL8177-treated patients versus 33% (1 of 3) on placebo.
Price Action: ABVX stock is trading higher by 428.6% to $52.11 during the premarket session at last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/07/46551495/drug-innovation-at-risk-by-trump-budget-says-congressional-budget-office" target="_blank" rel="noreferrer noopener">Drug Innovation At Risk By Trump Budget, Says Congressional Budget Office</a></li>
</ul>
Photo via Shutterstock

Biotech

Health Care

Movers

General

ABVX

Abivax Stock Skyrockets On Strong Data From Inflammatory Bowel Disorder Study

CORRECTION: Hasbro Q2 Adj. EPS $1.30 Beats $0.76 Estimate, Sales $980.80M Beat $874.28M Estimate

JMP Securities analyst Jason Butler maintains Abivax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABVX#NASDAQ">ABVX</a>) with a Market Outperform and raises the price target from $33 to $95.

Price Target

Analyst Ratings

JMP Securities Maintains Market Outperform on Abivax, Raises Price Target to $95

Piper Sandler analyst Michael Lavery maintains Hershey (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSY#NYSE">HSY</a>) with a Underweight and raises the price target from $120 to $145.

Piper Sandler Maintains Underweight on Hershey, Raises Price Target to $145

ANEB

Trading Halt: Halted at 7:25:00 a.m. ET - Trading Halt: Halt News Pending

Guidance

Hasbro Sees FY25 Revenue Up Mid-Single Digits; Sees Adj. Operating Margin 22%-23% Vs 21%-22% Prior; Sees Adj. EBITDA $1.17B-$1.2B Vs $1.1B-$1.15B Prior

JMP Securities analyst Patrick Walravens maintains SAP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAP#NYSE">SAP</a>) with a Market Outperform and raises the price target from $330 to $375.

JMP Securities Maintains Market Outperform on SAP, Raises Price Target to $375

Dr Reddy's Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDY#NYSE">RDY</a>) reported quarterly earnings of $0.20 per share which beat the analyst consensus estimate of $0.19 by 5.26 percent. This is unchanged from the same period last year. The company reported quarterly sales of $997.000 million which beat the analyst consensus estimate of $950.920 million by 4.85 percent. This is a 8.38 percent increase over sales of $919.880 million the same period last year.

Dr Reddy's Laboratories Q1 EPS $0.20 Beats $0.19 Estimate, Sales $997.000M Beat $950.920M Estimate

Wolfe Research analyst Doug Leggate downgrades Imperial Oil (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IMO#AMEX">IMO</a>) from Outperform to Peer Perform.

Downgrades

Wolfe Research Downgrades Imperial Oil to Peer Perform

Rosenblatt analyst Blair Abernethy maintains RedCloud Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCT#NASDAQ">RCT</a>) with a Buy and maintains $5 price target.

Rosenblatt Maintains Buy on RedCloud Holdings, Maintains $5 Price Target

WIIM

MCHP

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

Shares of chip stocks are trading lower in possible sympathy with Texas Instruments, which fell after issuing Q3 outlook.

PONY

PONY AI shares are trading higher after the company began Gen‑7 robotaxi road testing in Beijing.

ENPH

Enphase Energy shares are trading lower after the company issued Q3 guidance with a midpoint below estimates.

TE Connectivity Sees Q4 GAAP EPS $2.18 vs $2.13 Est

Rosenblatt analyst Mike Genovese maintains Calix (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CALX#NYSE">CALX</a>) with a Buy and maintains $65 price target.

CALX

Rosenblatt Maintains Buy on Calix, Maintains $65 Price Target

PWR moves up over 12 points
<figure class="wp-block-image size-large"><img decoding="async" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/22203847/Screenshot-2025-07-22-at-4.37.58%E2%80%AFPM-942x1024.png" alt="" class="wp-image-16287" /></figure>
Quantas Services Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PWR#NYSE">PWR</a>) today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions. 
Today, at 10:03 AM on July 22nd, a significant trading signal occurred for Quantas Services Inc. (PWR) as it demonstrated a Power Inflow at a price of $383.33 This indicator is crucial for traders who want to know directionally where institutions and so-called "smart money" moves in the market. They see the value of utilizing order flow analytics to guide their trading decisions. The Power Inflow points to a possible uptrend in Quantas's stock, marking a potential entry point for traders looking to capitalize on the expected upward movement. Traders with this signal closely watch for sustained momentum in Quantas's stock price, interpreting this event as a bullish sign.
Signal description
Order flow analytics, aka transaction or market flow analysis, separate and study both the retail and institutional volume rate of orders (flow). It involves analyzing the flow of buy and sell orders, along with size, timing, and other associated characteristics and patterns, to gain insights and make more informed trading decisions. This particular indicator is interpreted as a bullish signal by active traders.&nbsp;
The Power Inflow occurs within the first two hours of the market open and generally signals the trend that helps gauge the stock's overall direction, powered by institutional activity in the stock, for the remainder of the day.&nbsp;
By incorporating order flow analytics into their trading strategies, market participants can better interpret market conditions, identify trading opportunities, and potentially improve their trading performance. But let's not forget that while watching smart money flow can provide valuable insights, it is crucial to incorporate effective risk management strategies to protect capital and mitigate potential losses. Employing a consistent and effective risk management plan helps traders navigate the uncertainties of the market in a more controlled and calculated manner, increasing the likelihood of long-term success
If you want to stay updated on the latest options trades for PWR,<a href="https://benzinga.grsm.io/register174"> Benzinga Pro</a> gives you real-time options trades alerts.&nbsp;
<a href="https://benzinga.com/apis?_gl=1&#x2A;1hlgn5i&#x2A;_ga&#x2A;MTY1NjE2NTYxMi4xNzE0NzQ4MTAy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDc0ODEwMi4xLjEuMTcxNDc0ODQyOC4wLjAuMA..">Market News and Data brought to you by Benzinga APIs</a> and include firms, like&nbsp; <a href="https://tradepulse.net/?utm_source=Benzinga&amp;utm_medium=Article&amp;utm_campaign=brand_awareness_July2025">https://tradepulse.net/?utm_source=Benzinga&amp;utm_medium=Article&amp;utm_campaign=brand_awareness_July2025</a>
which are responsible for parts of the data within this article.
After Market Close UPDATE:
The price at the time of the Power Inflow was $383.33. The returns on the High price ($395.81) and Close price ($394.86) after the Power Inflow are respectively 3.3% and 3.0%. The result underlines the importance of a trading plan that includes Profit Targets and Stop Losses that reflect your risk appetite.
Past performance is not indicative of future results

Equities

Opinion

Signals

Trading Ideas

Quanta Services Rises 3.3% After Key Signal, Reversing Early Downtrend

Ethereum's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) recent price rally is being driven by a sharp imbalance between <a href="https://www.benzinga.com/markets/25/07/46535957/ethereum-roars-to-3-800-whats-driving-the-surge">new supply and institutional demand</a>, according to Bitwise Chief Investment Officer Matt Hougan.
What Happened: In an X thread <a href="https://x.com/Matt_Hougan/status/1947754601530429453">posted</a> on Tuesday, Hougan cited data showing that Ethereum exchange-traded products (ETPs) and corporate treasuries have purchased over 2.83 million ETH since mid-May, more than 32 times the net new supply generated by the network in the same period.
Hougan's analysis follows Ethereum's 50% price increase in the past month and a more than 150% rise since its April lows. 
The surge, he says, is not speculative but rather grounded in fundamentals.
"ETPs and Corporate Treasuries have combined to buy 2.83 million ETH since May 15—more than $10 billion at today's prices. That&#8217;s 32x net new supply," Hougan wrote.
ETH's rally marks a shift from earlier in the year. 
For the first four months of 2025, Ethereum's price declined as demand for ETPs remained muted. 
Between the launch of ETH ETPs in July 2024 and May 15, 2025, total ETH purchases by these vehicles stood at just 660,000 ETH, nearly matched by 543,000 ETH in new issuance over the same period. 
The result: flat price action.
Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46528570/is-1m-bitcoin-realistic-tom-lee-says-it-may-be-closer-than-you-think">Is $1M Bitcoin Realistic? Tom Lee Says It May Be Closer Than You Think</a>
That changed rapidly in May, Hougan said, as both institutional demand and new corporate treasury strategies picked up pace. 
Firms such as Bitmine (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BMNR#AMEX">BMNR</a>) and SharpLink (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBET#NASDAQ">SBET</a>) have publicly disclosed Ethereum holdings, and inflows into spot ETH ETPs have topped $5 billion since mid-May.
What&#8217;s Next: While Ethereum's market cap is roughly 19% the size of Bitcoin's, ETH ETPs have gathered less than 12% of the assets compared to Bitcoin ETPs, according to Hougan.
He suggests this asset gap may continue to narrow as demand persists.
Hougan added that corporate interest appears to be rising, citing signs that companies holding ETH in their treasuries are trading at a premium relative to the value of their assets, a dynamic that historically supports further accumulation.
Though Ethereum's monetary policy differs from Bitcoin's—ETH does not have a hard supply cap—Hougan emphasized that short-term price action is driven by basic supply and demand.
"All signs suggest the ‘ETH treasury company' trend will accelerate," he wrote. "In the short term, the price of everything is set by supply and demand."
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46527426/ethereum-xrp-sol-surge-after-genius-act-whats-driving-the-altcoin-rally">Ethereum, XRP, SOL Surge After GENIUS Act: What&#8217;s Driving The Altcoin Rally?</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Comments

Direxion Daily S&P 500 Bear 3X

Notizie

Ultime notizie per Direxion Daily S&P 500 Bear 3X (ARCA:SPXS)

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO